RCS - Avacta Group PLC - Turner Pope Investor Evening
RNS Number : 6749CAvacta Group PLC19 June 2019
19 June 2019
Avacta Group plc
("Avacta", the "Company" or the "Group")
Turner Pope Investor Evening
Avacta Group plc (AIM: AVCT.L), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that the Group's Chief Executive, Alastair Smith, will be presenting at an investor evening hosted by Turner Pope Investments on Wednesday, 3 July 2019. The event will be held in London, EC2 and commence at 4pm.
To register your interest, please email info@turnerpope.com or call on 0203 621 4124.
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel: +44 (0) 844 414 0452
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Giles Rolls - Corporate Finance
Tim Redfern - ECM
WG Partners (Joint Broker)
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang
Tel: +44 (0) 207 220 0500
www.finncap.com
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
Turner Pope Investments
James Pope / Ben Turner
Yellow Jersey PR (Financial Media and IR)
Sarah Hollins
Harriet Jackson
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0) 203 621 4120
www.turnerpope.com
Tel: +44 (0)7764 947 137
Tel: +44 (0)7544 275 882
Tel: +44 (0)7787 502 947
katie.odgaard@zymecommunications.com
About Avacta Group plc - https://www.avacta.com
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDNRALLFFRRIITLIA
Recent news on Avacta
See all newsREG - Avacta Group PLC - Block Listing Application to AIM
AnnouncementREG - AIM - AIM Notice - 23/04/2024
AnnouncementREG - Avacta Group PLC - Notice of Results
AnnouncementREG - Avacta Group PLC - Issue of Equity and Total Voting Rights
AnnouncementREG - Avacta Group PLC - Avacta Reports Data at the AACR Annual Meeting
Announcement